甲磺酸氟马替尼
基本信息
产品名称：
甲磺酸氟马替尼
英文名称：
Flumatinib mesylate
国产/进口：
进口
产地/品牌：
美国/TargetMol
型号：
参考报价：
面议
销售商：
总点击数：
29
更新日期：
2025-05-27
产品类别：
性能参数
Product Introduction
Bioactivity
英文名: Flumatinib mesylate
描述: Flumatinib mesylate (HHGV678 mesylate) 是一种具有口服活性的选择性Bcr-Abl 抑制剂，能够作用于 c-Abl (IC50:1.2 nM)，PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。
体外活性: In vivo study consistently suggested that flumatinib had superior efficacy compared with imatinib or sunitinib against 32D cells with the secondary mutation Y823D.?Molecular modeling of flumatinib docked to the KIT kinase domain suggested a special mechanism underlying the capability of flumatinib to overcome the drug-resistance conferred by activation loop mutations.?These findings suggest that flumatinib could be a promising therapeutic agent against GISTs resistant to both imatinib and sunitinib because of secondary mutations in the activation loop[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 50 mg/mL (75.91 mM)
DMSO : 50 mg/mL (75.91 mM)
关键字: HHGV-678 | PDGFRβ | HHGV678 | c-Abl | Bcr-Abl | Platelet-derived growth factor receptor | Flumatinib Mesylate | PDGFR | HHGV 678 | HHGV-678 Mesylate | SCFR | Flumatinib mesylate | c-Kit | Flumatinib | CD117 | HHGV 678 Mesylate | Inhibitor | HHGV678 Mesylate | inhibit
相关产品: Olverembatinib | GNF-7 | Rigosertib | Dasatinib monohydrate | SIAIS178 | PPY A | Nilotinib | URMC-099 | Imatinib | Ponatinib
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library
Bioactivity
英文名: Flumatinib mesylate
描述: Flumatinib mesylate (HHGV678 mesylate) 是一种具有口服活性的选择性Bcr-Abl 抑制剂，能够作用于 c-Abl (IC50:1.2 nM)，PDGFRβ (IC50:307.6 nM) 和 c-Kit (IC50:665.5 nM)。
体外活性: In vivo study consistently suggested that flumatinib had superior efficacy compared with imatinib or sunitinib against 32D cells with the secondary mutation Y823D.?Molecular modeling of flumatinib docked to the KIT kinase domain suggested a special mechanism underlying the capability of flumatinib to overcome the drug-resistance conferred by activation loop mutations.?These findings suggest that flumatinib could be a promising therapeutic agent against GISTs resistant to both imatinib and sunitinib because of secondary mutations in the activation loop[1].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 50 mg/mL (75.91 mM)
DMSO : 50 mg/mL (75.91 mM)
关键字: HHGV-678 | PDGFRβ | HHGV678 | c-Abl | Bcr-Abl | Platelet-derived growth factor receptor | Flumatinib Mesylate | PDGFR | HHGV 678 | HHGV-678 Mesylate | SCFR | Flumatinib mesylate | c-Kit | Flumatinib | CD117 | HHGV 678 Mesylate | Inhibitor | HHGV678 Mesylate | inhibit
相关产品: Olverembatinib | GNF-7 | Rigosertib | Dasatinib monohydrate | SIAIS178 | PPY A | Nilotinib | URMC-099 | Imatinib | Ponatinib
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library
公司简介
TargetMol（陶术）作为一家全球性的生物医药领域高科技企业，我们致力于为高校、研究所、医院、企业等各类生物医药研发机构提供优质的产品和服务，为全球医药科学家更高效地完成科研工作助力。可提供20,000+种 抑制剂和激动剂 、800+种 化合物库 、19,000+种 天然产物 ，以及9,000+种 重组蛋白 、多种 多肽 、抗体 和 生命科学试剂盒 等。此外，在上海，TargetMol研发中心配备了 CADD & AIDD研究中心、药理实验室和药物化学合成 平台三大技术中心，可提供虚拟筛选、化合物活性测试、分子间结合力检测和化合物结构优化等技术服务，多方位满足用户的研发需求。
售后服务
相关视频
暂无
资料下载
暂无
联系方式
| 单位名称： |
|
详细地址：
静安区江场三路238号
|
|
qq：
2881954871
|
|
联系电话：
021-33632979
|
| Email： |
